Astrana Health closes $708 million Prospect Health deal, updates 2025 guidance
Astrana Health completed its acquisition of Prospect Health on July 1, 2025, paying $707.9 million in cash after a letter agreement cut the price from $745.0 million. The company updated its full-year 2025 revenue and adjusted EBITDA guidance to reflect a half-year contribution from Prospect and reaffirmed its second-quarter guidance. After the close, Astrana expects about $700 million of net debt, and shareholders will watch its plan to reduce net leverage below 2.5x over the next twelve to eighteen months.
Key points
- Acquisition closed July 1, 2025; cash price reduced from $745.0 million to $707.9 million under a letter agreement with the sellers.
- Full-year 2025 guidance now calls for total revenue of $3.1 billion to $3.3 billion and adjusted EBITDA of $215 million to $225 million.
- Second-quarter 2025 guidance was reiterated.
- About $700 million of net debt after close; management targets net leverage below 2.5x within twelve to eighteen months.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 02, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.